{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:10:20Z","timestamp":1761225020307,"version":"build-2065373602"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001428","name":"Amity University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.drudis.2020.10.029","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T22:28:11Z","timestamp":1604442491000},"page":"532-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A therapeutic update on PARP inhibitors: implications in the treatment of glioma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-3693","authenticated-orcid":false,"given":"Samridhi","family":"Lal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2766-4491","authenticated-orcid":false,"given":"Timothy J.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.drudis.2020.10.029_bib0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.drudis.2020.10.029_bib0010","article-title":"Molecular function of PARP inhibition in glioblastoma","volume":"77","author":"Aldrighetti","year":"2017","journal-title":"Cancer Res."},{"issue":"15017","key":"10.1016\/j.drudis.2020.10.029_bib0015","first-page":"17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.drudis.2020.10.029_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-12048-5_2","article-title":"Glioma biology and molecular markers","volume":"163","author":"Cohen","year":"2015","journal-title":"Cancer Treat Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3240","article-title":"A systematic analysis of the PARP protein family identifies new functions critical for cell physiology","volume":"4","author":"Vyas","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2020.10.029_bib0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.drudis.2020.10.029_bib0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1101\/gad.291518.116","article-title":"PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes","volume":"31","author":"Gupte","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.drudis.2020.10.029_bib0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.molcel.2015.01.034","article-title":"Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance","volume":"58","author":"Bai","year":"2015","journal-title":"Mol. Cell."},{"key":"10.1016\/j.drudis.2020.10.029_bib0045","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.drudis.2020.10.029_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.drudis.2020.10.029_bib0055","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1042\/BST20180418","article-title":"PARPs in genome stability and signal transduction: implications for cancer therapy","volume":"46","author":"Palazzo","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.drudis.2020.10.029_bib0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-12-0163","article-title":"Molecular pathways: targeting PARP in cancer treatment","volume":"19","author":"Do","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.drudis.2020.10.029_bib0065","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.drudis.2020.10.029_bib0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2020.10.029_bib0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0090","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1039\/C2CE26528A","article-title":"Temozolomide hydrochloride dihydrate","volume":"15","author":"Babu","year":"2013","journal-title":"CrystEngComm."},{"key":"10.1016\/j.drudis.2020.10.029_bib0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ana.410170116","article-title":"In vivo measurement of brain tumor pH using 11CDMO and positron emission tomography","volume":"17","author":"Rottenberg","year":"1985","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/cns.12.13","article-title":"The potential of PARP inhibitors in neuro-oncology","volume":"1","author":"Carruthers","year":"2012","journal-title":"CNS Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40164-019-0154-9","article-title":"Advances and perspectives of PARP inhibitors","volume":"8","author":"Yi","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0005-2787(75)90158-6","article-title":"Stimulation of nuclear poly(adenosine diphosphate-ribose) polymerase activity from HeLa cells by endonucleases","volume":"395","author":"Miller","year":"1975","journal-title":"Biochim. Biophys. Acta (BBA) Nucleic Acids Protein Synthesis"},{"key":"10.1016\/j.drudis.2020.10.029_bib0115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1042\/bj1850775","article-title":"Novel inhibitors of poly(ADP-ribose) synthetase","volume":"185","author":"Purnell","year":"1980","journal-title":"Biochem. J."},{"key":"10.1016\/j.drudis.2020.10.029_bib0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/09553009014550871","article-title":"Trends and developments in radioprotection: the effect of nicotinamide on DNA repair","volume":"57","author":"Riklis","year":"1990","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161209787185823","article-title":"Niacin status, NAD distribution and ADP-ribose metabolism","volume":"15","author":"Kirkland","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2020.10.029_bib0130","doi-asserted-by":"crossref","first-page":"157591","DOI":"10.4061\/2010\/157591","article-title":"Role of nicotinamide in DNA damage, mutagenesis, and DNA repair","volume":"2010","author":"Surjana","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.drudis.2020.10.029_bib0135","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","article-title":"PARP inhibition in cancer: an update on clinical development","volume":"14","author":"Sachdev","year":"2019","journal-title":"Target Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2020.10.029_bib0145","first-page":"107","article-title":"Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase","volume":"6","author":"Suto","year":"1991","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.drudis.2020.10.029_bib0150","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0021-9258(18)45983-2","article-title":"Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase","volume":"267","author":"Banasik","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2020.10.029_bib0155","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bjc.1998.670","article-title":"Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064","volume":"78","author":"Bowman","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drudis.2020.10.029_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500904X","article-title":"PARP inhibitors for cancer therapy","volume":"7","author":"Curtin","year":"2005","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.drudis.2020.10.029_bib0165","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/jm100012m","article-title":"Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors from concept to clinic","volume":"53","author":"Ferraris","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.10.029_bib0170","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.drudis.2020.10.029_bib0175","doi-asserted-by":"crossref","first-page":"984","DOI":"10.18632\/oncotarget.362","article-title":"PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation","volume":"2","author":"van Vuurden","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2020.10.029_bib0180","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"issue":"Suppl","key":"10.1016\/j.drudis.2020.10.029_bib0185","article-title":"Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)","volume":"35","author":"Halford","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0190","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drudis.2020.10.029_bib0195","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","author":"Hanna","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0200","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1634\/theoncologist.2019-0603","article-title":"Treatment of pediatric glioblastoma with combination olaparib and temozolomide demonstrates 2-year durable response","volume":"25","author":"Valiakhmetova","year":"2020","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.drudis.2020.10.029_bib0205","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.3390\/ijms21144910","article-title":"Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma","volume":"21","author":"Ferri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2020.10.029_bib0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1186\/s12885-016-2656-8","article-title":"An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma","volume":"16","author":"Nile","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2020.10.029_bib0215","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","article-title":"Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial","volume":"6","author":"Thomas","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2020.10.029_bib0220","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drudis.2020.10.029_bib0225","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-15-0553","article-title":"Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system","volume":"14","author":"Parrish","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2020.10.029_bib0230","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1535-7163.MCT-15-0282","article-title":"Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma","volume":"14","author":"Chornenkyy","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2020.10.029_bib0235","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0240","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.drudis.2020.10.029_bib0245","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/pbc.25201","article-title":"Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673","volume":"62","author":"Smith","year":"2015","journal-title":"Pediatr. Blood Cancer."},{"key":"10.1016\/j.drudis.2020.10.029_bib0255","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-17-0365","article-title":"Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2020.10.029_bib0260","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-14-0084","article-title":"ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy","volume":"20","author":"Lin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0265","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2147\/OTT.S69935","article-title":"Profile of veliparib and its potential in the treatment of solid tumors","volume":"8","author":"Wagner","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.drudis.2020.10.029_bib0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-017-1164-1","article-title":"Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma","volume":"15","author":"Jue","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drudis.2020.10.029_bib0275","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","article-title":"A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study","volume":"22","author":"Baxter","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"5","key":"10.1016\/j.drudis.2020.10.029_bib0280","first-page":"1","article-title":"Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma","volume":"108","author":"Gupta","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl","key":"10.1016\/j.drudis.2020.10.029_bib0285","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1538-7445.AM2015-1651","article-title":"BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models","volume":"75","author":"Tang","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0290","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumors: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0295","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1535-7163.MCT-07-0062","article-title":"The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity","volume":"6","author":"Miknyoczki","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl","key":"10.1016\/j.drudis.2020.10.029_bib0300","doi-asserted-by":"crossref","first-page":"B185","DOI":"10.1158\/1535-7163.TARG-11-B185","article-title":"Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors","volume":"10","author":"Mita","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2020.10.029_bib0305","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1158\/1078-0432.CCR-08-2079","article-title":"In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016","volume":"15","author":"Russo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0310","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/00003246-200205000-00019","article-title":"Novel phenanthridinone inhibitors of poly (adenosine 5\u2019-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents","volume":"30","author":"Jagtap","year":"2002","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.drudis.2020.10.029_bib0315","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/cancers12061628","article-title":"The modified phenanthridine PJ34 unveils an exclusive cell-death mechanism in human cancer cells","volume":"12","author":"Cohen-Armon","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2020.10.029_bib0320","doi-asserted-by":"crossref","first-page":"e114583","DOI":"10.1371\/journal.pone.0114583","article-title":"PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma","volume":"9","author":"Karpel-Massler","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.10.029_bib0325","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1021\/jm901775y","article-title":"Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor","volume":"53","author":"Penning","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.10.029_bib0330","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbrc.2017.08.018","article-title":"The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids","volume":"491","author":"Koosha","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2020.10.029_bib0335","first-page":"119818","article-title":"Selectivity profile of the poly(ADP-ribose) polymerase (PARP) inhibitor, A-966492","volume":"2017","author":"Thorsell","year":"2017","journal-title":"bioRxiv"},{"issue":"14","key":"10.1016\/j.drudis.2020.10.029_bib0340","first-page":"5370","article-title":"Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma","volume":"9","author":"Tentori","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0345","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hed.21195","article-title":"Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427","volume":"32","author":"Khan","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.drudis.2020.10.029_bib0350","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijbiomac.2020.02.069","article-title":"BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo","volume":"150","author":"Guo","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0355","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biochi.2020.03.003","article-title":"In vitro and computational studies of natural products related to perezone as anti-neoplastic agents","volume":"171\u2013172","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.drudis.2020.10.029_bib0360","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-016-2999-1","article-title":"Molecular chess? Hallmarks of anti-cancer drug resistance","volume":"17","author":"Cree","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2020.10.029_bib0365","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00301","article-title":"Structural implications for selective targeting of PARPs","volume":"3","author":"Steffen","year":"2013","journal-title":"Frontiers Oncol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0370","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/ijms18102111","article-title":"PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.drudis.2020.10.029_bib0375","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4081\/ejh.2012.e9","article-title":"PARP-1 protein expression in glioblastoma multiforme","volume":"56","author":"Galia","year":"2012","journal-title":"Eur. J. Histochem."},{"issue":"28","key":"10.1016\/j.drudis.2020.10.029_bib0380","doi-asserted-by":"crossref","first-page":"46348","DOI":"10.18632\/oncotarget.18013","article-title":"PARP1 expression and its correlation with survival is tumor molecular subtype dependent in glioblastoma","volume":"8","author":"Murny\u00e1k","year":"2017","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.drudis.2020.10.029_bib0385","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1007\/s00018-012-1003-8","article-title":"Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein","volume":"69","author":"Sz\u00e1nt\u00f3","year":"2012","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drudis.2020.10.029_bib0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2011.03.013","article-title":"PARP-2 regulates SIRT1 expression and whole-body energy expenditure","volume":"13","author":"Bai","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.drudis.2020.10.029_bib0395","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1242\/jcs.00341","article-title":"PARP-3 localizes preferentially to the daughter centriole and interferes with the G1\/S cell cycle progression","volume":"116","author":"Augustin","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.drudis.2020.10.029_bib0400","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jcb.21051","article-title":"PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery","volume":"100","author":"Rouleau","year":"2007","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.drudis.2020.10.029_bib0405","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1007\/s13277-015-3554-4","article-title":"PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance","volume":"36","author":"Quan","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0410","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1083\/jcb.146.5.917","article-title":"The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase","volume":"146","author":"Kickhoefer","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0415","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1530\/ERC-15-0359","article-title":"Germline PARP4 mutations in patients with primary thyroid and breast cancers","volume":"23","author":"Ikeda","year":"2016","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.drudis.2020.10.029_bib0420","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/cdd.2011.101","article-title":"Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation","volume":"19","author":"Ha","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drudis.2020.10.029_bib0425","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1038\/s41467-019-12377-1","article-title":"Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2020.10.029_bib0430","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.2147\/OTT.S206142","article-title":"Biological functions of TNKS1 and its relationship with Wnt\/\u03b2-catenin pathway in astrocytoma","volume":"12","author":"Chen","year":"2019","journal-title":"Onco. Targets Therapy."},{"key":"10.1016\/j.drudis.2020.10.029_bib0435","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/cancers12061630","article-title":"A small-molecule tankyrase inhibitor reduces glioma stem cell proliferation and sphere formation","volume":"12","author":"Kierulf-Vieira","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2020.10.029_bib0440","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1128\/MCB.26.6.2037-2043.2006","article-title":"Generation and characterization of telomere length maintenance in tankyrase 2-deficient mice","volume":"26","author":"Chiang","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0445","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3892\/ijo.2012.1652","article-title":"PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development","volume":"41","author":"Tuncel","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"14","key":"10.1016\/j.drudis.2020.10.029_bib0450","doi-asserted-by":"crossref","first-page":"18812","DOI":"10.18632\/oncotarget.7712","article-title":"PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer","volume":"7","author":"Qi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2020.10.029_bib0455","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/nar\/gks1337","article-title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation","volume":"41","author":"MacPherson","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drudis.2020.10.029_bib0460","doi-asserted-by":"crossref","first-page":"e0180682","DOI":"10.1371\/journal.pone.0180682","article-title":"Systematic screening for skin, hair, and nail abnormalities in a large\u2013scale knockout mouse program","volume":"12","author":"Sundberg","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.10.029_bib0465","doi-asserted-by":"crossref","DOI":"10.1111\/cns.13380","article-title":"Molecular and clinical characterization of PARP9 in gliomas: a potential immunotherapeutic target","author":"Xu","year":"2020","journal-title":"CNS Neurosci. Ther."},{"issue":"22","key":"10.1016\/j.drudis.2020.10.029_bib0470","doi-asserted-by":"crossref","first-page":"15201","DOI":"10.1074\/jbc.M506745200","article-title":"CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10)","volume":"281","author":"Chou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2020.10.029_bib0475","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/febs.12124","article-title":"Caspase-dependent cleavage of the mono-ADP-ribosyltransferase ARTD10 interferes with its pro-apoptotic function","volume":"280","author":"Herzog","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.drudis.2020.10.029_bib0480","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/sj.onc.1208410","article-title":"PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation","volume":"24","author":"Yu","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2020.10.029_bib0485","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41564-019-0428-3","article-title":"ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase \u03b2-TrCP","volume":"4","author":"Guo","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.drudis.2020.10.029_bib0490","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1095\/biolreprod.114.123661","article-title":"Spermatid head elongation with normal nuclear shaping requires ADP\u2013ribosyltransferase PARP11 (ARTD11) in mice","volume":"92","author":"Meyer-Ficca","year":"2015","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.drudis.2020.10.029_bib0495","doi-asserted-by":"crossref","first-page":"14035","DOI":"10.1038\/s41598-017-14156-8","article-title":"PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions","volume":"7","author":"Catara","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2020.10.029_bib0500","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molmed.2015.03.002","article-title":"Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer","volume":"21","author":"Todorova","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drudis.2020.10.029_bib0505","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1038\/ncomms8882","article-title":"PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation","volume":"6","author":"Iansante","year":"2015","journal-title":"Nat. Commun."},{"issue":"36","key":"10.1016\/j.drudis.2020.10.029_bib0510","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1038\/onc.2012.448","article-title":"Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma","volume":"32","author":"Barbarulo","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2020.10.029_bib0515","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1089\/gtmb.2016.0007","article-title":"Genetic association of PARP15 polymorphisms with clinical outcome of acute myeloid leukemia in a Korean population","volume":"20","author":"Lee","year":"2016","journal-title":"Genet Test Mol. Biomarkers."},{"key":"10.1016\/j.drudis.2020.10.029_bib0520","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ncb2593","article-title":"PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1\u03b1-mediated unfolded protein response","volume":"14","author":"Jwa","year":"2012","journal-title":"Nat. Cell Biol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620304657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620304657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:47:22Z","timestamp":1761223642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620304657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1359644620304657"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.10.029","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A therapeutic update on PARP inhibitors: implications in the treatment of glioma","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}